Market Research Report
Obesity - Pipeline Review, H2 2020
|Obesity - Pipeline Review, H2 2020|
Published: November 30, 2020
Global Markets Direct
Content info: 640 Pages
Delivery time: 1-2 business days
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Pipeline Review, H2 2020, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.
Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obesity - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 3, 23, 33, 4, 118, 48 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 54 and 13 molecules, respectively.
Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Table of Contents
Obesity- Therapeutics Development
Obesity- Therapeutics Assessment
Obesity- Companies Involved in Therapeutics Development
Obesity- Drug Profiles
Obesity- Dormant Projects
Obesity- Discontinued Products
Obesity- Product Development Milestones